| Assessment Status | Rapid Review Complete |
| HTA ID | 26017 |
| Drug | Infliximab induction phase of treatment in patients with rheumatoid arthritis |
| Brand | Remsima SC® |
| Indication | Infliximab (Remsima SC®) is indicated in combination with methotrexate, indicated in rheumatoid arthritis (RA) for the reduction of signs and symptoms as well as the improvement in physical function in: • Adult patients with active disease when the response to disease-modifying antirheumatic drugs (DMARDs), including methotrexate, has been inadequate. • Adult patients with severe, active and progressive disease not previously treated with methotrexate or other DMARDs*. Reimbursement is sought for the infliximab 120mg solution for injection in pre-filled pen (PFP) (pack of four pens) for the induction phase of treatment in patients with RA. |
| Assessment Process | |
| Rapid review commissioned | 08/04/2026 |
| Rapid review completed | 24/04/2026 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that infliximab SC (four PFPs per pack for induction treatment for patients with RA) not be considered for reimbursement at the submitted price*. |
Next steps: The NCPE Assessment Report and recommendation, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Further information on this process may be found here.